Current sort has key articles at the top. Click on "Article Date" to sort by date, click on specific "tag" to view all articles in that category.
| Title/Link | |
|---|---|
|
FDA Warning Letter Curaleaf [1] 07/29/2019 |
FDA has determined that your “CBD Lotion,” “CBD Pain-Relief Patch,” “CBD Tincture,” and “CBD Disposable Vape Pen” products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1). FDA has also determined that your “Bido CBD for Pets” products are unapproved new animal drugs that are unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5) FDA [2], Curaleaf [3] |
|
FDA warns company marketing unapproved cannabidiol products with unsubstantiated claims to treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety [4] 07/29/2019 |
Today, the U.S. Food and Drug Administration announced that it has issued a warning letter [5] to Curaleaf Inc., of Wakefield, Massachusetts, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases. FDA [2], Curaleaf [3] |
Links
[1] http://www.rethinkpot.org/fda-warning-letter-curaleaf
[2] http://www.rethinkpot.org/tags/fda
[3] http://www.rethinkpot.org/tags/curaleaf
[4] http://www.rethinkpot.org/fda-warns-company-marketing-unapproved-cannabidiol-products-unsubstantiated-claims-treat-cancer
[5] https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curaleaf-inc-579289-07222019